Sherbrooke Park Advisers LLC Fate Therapeutics Inc Transaction History
Sherbrooke Park Advisers LLC
- $436 Billion
- Q3 2024
A detailed history of Sherbrooke Park Advisers LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 138,339 shares of FATE stock, worth $232,409. This represents 0.11% of its overall portfolio holdings.
Number of Shares
138,339
Previous 28,652
382.82%
Holding current value
$232,409
Previous $94 Million
415.21%
% of portfolio
0.11%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding FATE
# of Institutions
175Shares Held
115MCall Options Held
53.7KPut Options Held
9K-
Redmile Group, LLC San Francisco, CA13.2MShares$22.1 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$17.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$17 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$9.36 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$8.82 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $163M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...